The FDA enforcement database lists a Class II recall, dated 14 October and ongoing, of compounded tirzepatide injection 18 mg/mL in 4 mL multi-dose vials from a US compounding pharmacy, for lack of assurance of sterility. It sits alongside recalls the same week of compounded tirzepatide and semaglutide syringes, some combined with cyanocobalamin, from another compounder.
A Class II recall indicates a risk of temporary or reversible harm, or a remote chance of serious harm. It concerns how these compounded products were made, not tirzepatide itself.
For clinical pharmacologists, multi-dose vials of compounded peptides add risks beyond sterility: dose drawn by the patient, uncertain potency and no stability data. The direct relevance to India is limited, but compounded and grey-market GLP-1 products are reaching patients here too.
- Ask patients on tirzepatide or semaglutide whether their product is licensed or compounded.
- Consider product contamination in injection-site infection or unexplained fever in compounded-product users.
- Multi-dose compounded vials add dosing and potency uncertainty to the sterility concern.
- Report suspected adverse reactions to compounded products to the national pharmacovigilance programme.
Why it matters
Compounded GLP-1 products carry manufacturing risks that the trial safety data for the licensed drugs do not cover.
Don't overread it
A Class II recall of compounded batches is not a safety finding about licensed tirzepatide.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for clinical pharmacology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free